Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index; 10 of the 14 sources its claims cite were checked for support.
Abstract
Background Immune checkpoint inhibitors (ICIs) are promising agents for unresectable hepatocellular carcinoma (uHCC), but lack effective biomarker to predict outcomes. The gut microbiome can modulate tumor response to immunotherapy, but its effect on HCC remains unclear. Methods From May 2018 to February 2020, patients receiving ICI treatment for uHCC were prospectively enrolled; their fecal samples were collected before treatment. The fecal microbiota and metabolites were analyzed from 20 patients with radiology-proven objective responses (OR) and 21 randomly selected patients with progressive disease (PD). After March 2020, 33 consecutive Child-Pugh-A patients were recruited as a validation cohort. Additionally, feces from 17 healthy volunteers were collected for comparison of background microbes. Results A significant dissimilarity was observed in fecal bacteria between patients with OR and patients with PD before immunotherapy. Prevotella 9 was enriched in patients with PD, whereas Lachnoclostridium, Lachnospiraceae, and Veillonella were predominant in patients with OR. Ursodeoxycholic acid and ursocholic acid were significantly enriched in the feces of patients with OR and strongly correlated with the abundance of Lachnoclostridium . The coexistence of Lachnoclostridium enrichment and Prevotella 9 depletion significantly predicted better overall survival (OS). In the validation cohort, better progression-free survival (PFS) and OS were noted in patients who had a preferable microbial signature in comparison with counter-group (PFS: 8.8 months vs 1.8 months; OS: not reached vs 6.5 months, both p<0.001). Conclusions Fecal microbiota and bile acids were associated with outcomes of immunotherapy for uHCC. These findings highlight the potential role of gut microbiota and metabolites as biomarkers to predict outcomes of ICI-treated HCC.
Overview
CoChat Summary
TL;DR
In a prospective biomarker study of immune checkpoint inhibitor (ICI)-treated unresectable hepatocellular carcinoma (uHCC), baseline fecal microbiota and bile acids differed between responders and progressors, and a microbial signature of Lachnoclostridium enrichment plus Prevotella 9 depletion predicted better survival. A validation cohort confirmed better progression-free and overall survival with this favorable signature.
Key findings
- Fecal bacteria differed significantly between objective responders (OR) and progressive disease (PD) before immunotherapy: Prevotella 9 was enriched in PD, whereas Lachnoclostridium, Lachnospiraceae, and Veillonella predominated in OR.
- Ursodeoxycholic acid (UDCA) and ursocholic acid (UCA) were significantly enriched in OR feces and strongly correlated with Lachnoclostridium abundance.
- Coexistence of Lachnoclostridium enrichment and Prevotella 9 depletion significantly predicted better overall survival (OS); in the validation cohort, this good microbial signature was associated with PFS of 8.8 months vs 1.8 months and OS not reached vs 6.5 months (both p<0.001).
- In the validation cohort, the best ORR was 52.6% and DCR was 94.7% in patients with the good microbial signature.
Methods
- Prospective enrollment from May 2018 to February 2020 of 94 ICI treatment-naïve patients with uHCC at Taipei Veterans General Hospital; fecal samples were collected before treatment. Discovery analysis compared 20 patients with radiology-proven OR (3 complete responses, 17 partial responses) and 21 randomly selected patients with PD; after March 2020, 33 consecutive Child-Pugh-A patients formed a validation cohort, and feces from 17 healthy volunteers were used for background comparison.
- Fecal microbiota was analyzed by 16S rRNA V3-V4 sequencing with QIIME/SILVA, PCoA of Bray-Curtis dissimilarity, PERMANOVA, LEfSe, and Spearman correlation; fecal bile acids were measured by UHPLC-MS/MS (39 BAs) and short-chain fatty acids by HPLC.
- Tumor response was assessed by RECIST V.1.1; OS and PFS were estimated by Kaplan-Meier and compared by log-rank test, with Cox proportional-hazard models for prognostic factors; p<0.05 was considered significant.
Limitations
- The paper states it could not determine causality between differential bacteria or metabolites and tumor outcomes; mechanistic associations between Lachnoclostridium and secondary bile acids need in vitro investigation; dynamic microbiota/metabolite sampling was not performed; findings may not apply to atezolizumab plus bevacizumab; not all patients had paired PBMC or biopsy samples; and most patients had viral-related HCC, so generalizability to non-viral HCC requires further study.
- Evident from the text: the discovery cohort was small (20 OR and 21 PD), and the validation cohort included 33 patients, limiting statistical power and broader generalizability.
- Evident from the text: more OR patients received ICI plus tyrosine kinase inhibitor combination therapy than PD patients (60.0% vs 23.8%, p=0.019), a potential baseline imbalance, although the authors report combination treatment was not a significant survival factor in their cohort.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
9 Valid · 0 Not valid · 2 Not checked · 38 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, our previous study showed that the composition of gut microbiota remained unchanged between paired fecal samples of the same patient collected at baseline and 8 weeks post-ICI treatment, thus indicating that ICI treatment would not alter the features of gut microbiome, and the effects of microbial changes might be less prominent on the treatment outcomes.33”
§ Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma > Discussion
What the sources say
- Supportedcites [33] Shen, 2021, An exploratory study for the association of gut microbiome with efficacy of immune checkpoint inhibitor in patients with hepatocellular carcinoma, J Hepatocell Carcinoma source
The Results section (“Gut Microbiome Compositions Were Not Associated with Efficacy”) reports that compositions did not change significantly after ICI and were relatively stable over the first 8 weeks. The study evaluated baseline and week-8 fecal samples from 20 patients, matching the claim’s paired-sample comparison. (LLM, conf=0.91)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The gut microbiome can modulate tumor response to immunotherapy, but its effect on HCC remains unclear.”
- Also stated in: § Introduction · hedged
“Emerging studies also indicate that the gut microbiome has a role in response to cancer therapy across cancer types.11 12”
§ Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma > Abstract > Background
What the sources say
- Supportedcites [11] source
The paper’s concluding passage states that the gut microbiome may modulate responses to anti-PD-1 immunotherapy in melanoma patients. Its fecal-transplant experiments also found improved responses to anti-PD-L1 therapy in mice receiving stool from responding patients. The citing sentence does not attribute a finding about HCC to this source. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [12] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the 33 patients in the validation cohort (baseline characteristics in online supplemental table 2), fecal enrichment of Lachnoclostridium was significantly associated with a better ORR and DCR of HCC.”
§ Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma > Results > Validation cohort
plainstates an associationn = 33- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Combination treatment was not a significant factor associated with survival in the studied cohort.”
§ Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Ursodeoxycholic acid and ursocholic acid were significantly enriched in the feces of patients with OR and strongly correlated with the abundance of Lachnoclostridium.”
- Also stated in: § Positive association of fecal metabolites with bacterial species · plain
“According to the Spearman correlation analysis (figure 3), the fecal concentrations of UDCA, UCA, and MDCA had significantly positive correlations with the relative abundance of Lachnoclostridium.”
§ Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma > Abstract > Results
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Positive association of fecal metabolites with bacterial species · plain
29 more claims
Create a free account to see all 49 claims and every source verdict.
- Probably not a substantial claim. 13
- It may state two separate claims as one. 6
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1186/s13099-019-0304-y”
Cited work 10.1186/s13099-019-0304-y · retracted 2026-09-18 · notice 10.1186/s13099-026-00882-w · this paper published 2022-06
Citations
Cites
1 retracted
Morgan, R. N., Saleh, S. E., Farrag, H. A., & Aboulwafa, M. (2019) · Gut Pathogens · doi:10.1186/s13099-019-0304-y · Cited by 48
RetractedQIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
The SILVA ribosomal RNA gene database project: improved data processing and web-based tools
Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., & Glöckner, F. O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1219 · Cited by 33,055
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,700
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Klindworth, A., Pruesse, E., Schweer, T., Peplies, J., Quast, C., Horn, M., & Glöckner, F. O. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks808 · Cited by 8,850
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2019) · International Journal of Cancer · doi:10.1002/ijc.31937 · Cited by 7,553
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Cited by
Mechanisms of drug resistance in HCC
Ladd, A. D., Duarte, S., Sahin, I., & Zarrinpar, A. (2024) · Hepatology · doi:10.1097/hep.0000000000000237 · Cited by 363
Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma
Chan, Y.-T., Zhang, C., Wu, J., Lu, P., Xu, L., Yuan, H., Feng, Y., Chen, Z.-S., & Wang, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02101-z · Cited by 281
Metabolic reprogramming in the tumor microenvironment of liver cancer
Lin, J., Rao, D., Zhang, M., & Gao, Q. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01527-8 · Cited by 251
“Lee et al. suggested that Lachnoclostridium , along with ursodeoxycholic and ursocholic acids, produce better responses to ICB treatment in patients with unresectable HCC [229].”
BackgroundA Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer Therapy
Yang, Q., Wang, B., Zheng, Q., Li, H., Meng, X., Zhou, F., & Zhang, L. (2023) · Advanced Science · doi:10.1002/advs.202207366 · Cited by 240
Critical role of the gut microbiota in immune responses and cancer immunotherapy
Li, Z., Xiong, W., Liang, Z., Wang, J., Zeng, Z., Kołat, D., Li, X., Zhou, D., Xu, X., & Zhao, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01541-w · Cited by 176
Metadata
- Authors
- Lee, P.-C., Wu, C.-J., Hung, Y.-W., Lee, C. J., Chi, C.-T., Lee, I.-C., Yu-Lun, K., Chou, S.-H., Luo, J.-C., Hou, M.-C., & Huang, Y.-H.
- Affiliations
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
- Biotools Co. Ltd, New Taipei City, Taiwan
- Corresponding author
- Huang, Yi-Hsiang
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2022-06
- Volume
- 10
- Issue
- 6
- Pages
- e004779
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC9226985
- OpenAlex
- W4283314687
- Semantic Scholar
- ba17ba65137d50666a0e60a34c2cfe287f8bc9a4
- Cited by
- 217
- References
- 53
- Citations by year
- 2026: 61 · 2025: 65 · 2024: 45 · 2023: 42 · 2022: 4
- FWCI
- 13.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Ministry of Science and Technology of Taiwan (MOST 108-2321-B-010 -017)
- Taipei Veterans General Hospital (V109C-048, V110C-144)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- gut microbiota, immune checkpoint inhibitors, unresectable hepatocellular carcinoma, fecal metabolites, bile acids, ursodeoxycholic acid, Lachnoclostridium, Prevotella 9, immunotherapy response prediction, prognostic factors, overall survival, progression-free survival
- MeSH terms
- Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma. https://app.cochat.ai/papers/10.1136/jitc-2022-004779
- The paper
- Lee, P.-C., Wu, C.-J., Hung, Y.-W., Lee, C. J., Chi, C.-T., Lee, I.-C., Yu-Lun, K., Chou, S.-H., Luo, J.-C., Hou, M.-C., & Huang, Y.-H. (2022). Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-004779
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.